PC
ALXN

Polar Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Polar Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$40.1M Buy
350,000
+85,000
+32% +$9.17M 0.3% 89
2020
Q2 		$29.7M Sell
265,000
-80,934
-23% -$8.59M 0.26% 104
2020
Q1 		$31.1M Sell
345,934
-90,000
-21% -$8.83M 0.33% 92
2019
Q4 		$47.1M Buy
435,934
+110,934
+34% +$11.9M 0.41% 72
2019
Q3 		$31.8M Sell
325,000
-353,592
-52% -$39.9M 0.29% 109
2019
Q2 		$88.9M Buy
678,592
+219,500
+48% +$28.3M 0.78% 29
2019
Q1 		$62.1M Buy
459,092
+43,092
+10% +$5.36M 0.58% 53
2018
Q4 		$40.5M Buy
416,000
+15,000
+4% +$1.77M 0.43% 75
2018
Q3 		$55.7M Buy
401,000
+186,000
+87% +$23.3M 0.47% 67
2018
Q2 		$26.7K Buy
215,000
+90,000
+72% +$10.5M 0.16% 129
2018
Q1 		$13.9M Sell
125,000
-441,371
-78% -$52.8M 0.14% 162
2017
Q4 		$67.7M Buy
566,371
+33,371
+6% +$4.06M 0.7% 29
2017
Q3 		$74.8M Buy
533,000
+368,288
+224% +$50M 0.84% 29
2017
Q2 		$20M Sell
164,712
-273,522
-62% -$31.8M 0.27% 121
2017
Q1 		$53.1M Sell
438,234
-22,916
-5% -$2.95M 0.8% 35
2016
Q4 		$56.4M Buy
461,150
+439,900
+2,070% +$53.8M 0.9% 26
2016
Q3 		$2.6M Buy
21,250
+11,730
+123% +$1.51M 0.05% 206
2016
Q2 		$1.11M Sell
9,520
-15,799
-62% -$2.24M 0.02% 240
2016
Q1 		$3.52M Sell
25,319
-162,334
-87% -$23.8M 0.07% 192
2015
Q4 		$35.8M Buy
187,653
+6,798
+4% +$1.19M 0.65% 49
2015
Q3 		$28.3M Sell
180,855
-444
-0.2% -$81K 0.57% 50
2015
Q2 		$32.8M Buy
181,299
+170,245
+1,540% +$29.4M 0.63% 48
2015
Q1 		$1.92M Buy
11,054
+5,664
+105% +$1.03M 0.04% 223
2014
Q4 		$997K Sell
5,390
-88,743
-94% -$16.4M 0.02% 239
2014
Q3 		$15.6M Sell
94,133
-13,144
-12% -$2.16M 0.33% 98
2014
Q2 		$16.8M Buy
+107,277
New +$16.9M 0.36% 102

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Capital's ALXN Position: Q3 2020 in Review

Polar Capital increased its Alexion Pharmaceuticals (ALXN) stake by 32% in Q3 2020, buying an estimated $9.17M and bringing the position to 350,000 shares worth $40.1M. The position accounts for 0.3% of the portfolio, ranked #89.

Polar Capital first reported a position in ALXN in Q2 2014 and has held it in 26 quarters since. The position peaked at $88.9M in Q2 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Polar Capital held 350,000 shares of Alexion Pharmaceuticals worth $40.1M as of Q3 2020.
  • Polar Capital bought 85,000 Alexion Pharmaceuticals shares in Q3 2020, an estimated $9.17M.
  • Alexion Pharmaceuticals made up 0.3% of Polar Capital's portfolio in Q3 2020, its #89 holding.
  • Polar Capital first reported a position in Alexion Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
  • Polar Capital's Alexion Pharmaceuticals position peaked at $88.9M in Q2 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.